Lung Cancer News and Research

Latest Lung Cancer News and Research

Vitamin D may not ward off Type 2 diabetes

Vitamin D supplementation is unlikely to improve glycaemic measures in people with prediabetes, show the findings of a randomised trial.

30 Jun 2014

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

30 Jun 2014

Study offers detailed insights into homeless, alcohol-dependent patients

A phenomenological study offers detailed insights into homeless, alcohol-dependent patients often stigmatized by the public and policymakers as drains on the health care system, showing the constellation of reasons they are incapable of escaping social circumstances that perpetuate and exacerbate their problems.

28 Jun 2014

University of Louisville researchers take a step forward in battle against lung cancer

Researchers at the University of Louisville have uncovered a cadre of small molecules that tell certain proteins to kill lung cancer cells. The team, led by Chi Li, Ph.D., assistant professor of medicine, published its finding in the April 2014 issue of Molecular and Cellular Biology.

28 Jun 2014

Surgical biopsies can be safely performed on selected patients with late-stage lung cancer

Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor (EGFR).

27 Jun 2014

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

Exchange plans attract sicker consumers

An analysis of early medical claims shows that Americans enrolled in the health law's exchange plans have higher rates of serious health problems, according to The Wall Street Journal. Meanwhile, The Washington Post reports that some small employers buying coverage for their workers are struggling with costs and logistics.

26 Jun 2014

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Erlotinib can be intercalated with the anti-tubule agent eribulin mesylate for patients with advanced non-small-cell lung cancer but it is unlikely to increase treatment efficacy in those without epidermal growth factor receptor activating mutations, research suggests.

25 Jun 2014

First Edition: June 25, 2014

Today's headlines include a report about a recent analysis that finds new health plan enrollees are showing high rates of serious health conditions.

25 Jun 2014

Key historical misconceptions hinder research and treatment for brain metastases

"Key historical misconceptions" are hindering progress in research and treatment for patients with cancer metastases to the brain, suggests a special article in the July issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

25 Jun 2014

New study explores effects of immunotherapy, chemotherapy drugs on non-small cell lung cancer

A new study offered at Houston Methodist Hospital will compare an emerging immunotherapy drug to an existing chemotherapy drug and look at the effects both drugs have on the development of non-small cell lung cancer, a type of cancer which makes up about 85 percent of lung cancer cases.

24 Jun 2014

Colon has safety mechanism to restrict formation and growth of adenomas

Colon cancer development starts with the formation of benign tumours called adenomas. It is estimated that between 30% and 50% of people over 50 will develop one of these tumours.

24 Jun 2014

Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Phase II study findings show only marginal positive effects of third-line treatment with afatinib for advanced non-small-cell lung cancer in patients with wild-type epidermal growth-factor receptor tumour status.

23 Jun 2014

Clovis Oncology begins TIGER2 study for treatment of NSCLC patients with EGFR/T790M mutations

Clovis Oncology, Inc. announced today that the TIGER2 study has commenced with the dosing of the first patient at a U.S. study site.

23 Jun 2014

Six-gene signature predicts survival after targeted therapy for NSCLC

The presence of a six-gene profile in the microRNA of patients with advanced non-squamous non-small-cell lung cancer predicts reduced survival likelihood after first-line treatment with targeted therapy followed by chemotherapy for disease progression, indicate research results.

20 Jun 2014

FGFR1 amplification predicts poor outcome in early-stage NSCLC

Amplification of fibroblast growth factor receptor 1 is associated with poor clinical outcome in patients with early-stage non-small-cell lung cancer, Swiss researchers report.

20 Jun 2014

SCLC tumours replicated in mice from patients' CTCs

Scientists have used circulating tumour cells taken from patients with small-cell lung cancer to grow explant tumours in mice that retain the original’s morphological and genetic characteristics.

20 Jun 2014

UCLA study sheds light on the development of lung cancer

UCLA researchers led by Dr. Brigitte Gomperts have discovered the inner workings of the process thought to be the first stage in the development of lung cancer. Their study explains how factors that regulate the growth of adult stem cells that repair tissue in the lungs can lead to the formation of precancerous lesions.

20 Jun 2014

Clinically relevant mouse model for difficult-to-treat squamous cell lung cancer

Only 15% of patients with squamous cell lung cancer - the second most common lung cancer - survive five years past diagnosis.

20 Jun 2014

Emphysema does not worsen lung cancer prognosis beyond pulmonary fibrosis

Patients with combined pulmonary fibrosis and emphysema who are undergoing treatment for advanced lung cancer do not have a significantly worse prognosis than their counterparts with isolated idiopathic interstitial pneumonias, report Japanese researchers.

19 Jun 2014

Lung Cancer News and Research

Latest Lung Cancer News and Research

Vitamin D may not ward off Type 2 diabetes

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Study offers detailed insights into homeless, alcohol-dependent patients

University of Louisville researchers take a step forward in battle against lung cancer

Surgical biopsies can be safely performed on selected patients with late-stage lung cancer

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

Exchange plans attract sicker consumers

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

First Edition: June 25, 2014

Key historical misconceptions hinder research and treatment for brain metastases

New study explores effects of immunotherapy, chemotherapy drugs on non-small cell lung cancer

Colon has safety mechanism to restrict formation and growth of adenomas

Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Clovis Oncology begins TIGER2 study for treatment of NSCLC patients with EGFR/T790M mutations

Six-gene signature predicts survival after targeted therapy for NSCLC

FGFR1 amplification predicts poor outcome in early-stage NSCLC

SCLC tumours replicated in mice from patients' CTCs

UCLA study sheds light on the development of lung cancer

Clinically relevant mouse model for difficult-to-treat squamous cell lung cancer

Emphysema does not worsen lung cancer prognosis beyond pulmonary fibrosis

The ultimate guide to lung research tools and protocols eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in